165 related articles for article (PubMed ID: 37601130)
1. Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children.
Xie J; Liu S; Zhou M; Wang Y; He H; Xiao P; Hu S; Lu J
Front Pediatr; 2023; 11():1187607. PubMed ID: 37601130
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia.
Pawinska-Wasikowska K; Wieczorek A; Balwierz W; Bukowska-Strakova K; Surman M; Skoczen S
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053619
[TBL] [Abstract][Full Text] [Related]
3. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
[TBL] [Abstract][Full Text] [Related]
4. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
6. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis.
Yoon JH; Kwag D; Lee JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Wook Lee J; Lee S
Ther Adv Hematol; 2023; 14():20406207231154713. PubMed ID: 36895914
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
[TBL] [Abstract][Full Text] [Related]
8. Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study.
Wang S; Liu A; Wang N; Wang Y; Zhang A; Wang L; Yu W; Li C; Zhang Y; Hu Q
Front Pediatr; 2022; 10():1100404. PubMed ID: 36727001
[TBL] [Abstract][Full Text] [Related]
9. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
10. [Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia].
Li XL; Liu LP; Liu F; Guo Y; Chen XJ; Zhu XF; Yang WY
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Apr; 25(4):374-380. PubMed ID: 37073842
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
[TBL] [Abstract][Full Text] [Related]
12. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
13. [Targeted immunotherapy efficacy analysis in patients with relapsed/refractory B cell acute lymphocytic leukemia].
Su Y; Bao S; Wei YP; Song LJ; Xue YM; Wei XD; Song YP; Yin QS
Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):946-951. PubMed ID: 36709187
[No Abstract] [Full Text] [Related]
14. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
Topp MS; Stein AS; Gökbuget N; Horst HA; Boissel N; Martinelli G; Kantarjian H; Brüggemann M; Chen Y; Zugmaier G
Cancer Med; 2021 Apr; 10(8):2601-2610. PubMed ID: 33734596
[TBL] [Abstract][Full Text] [Related]
15. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
16. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Stein AS; Kantarjian H; Gökbuget N; Bargou R; Litzow MR; Rambaldi A; Ribera JM; Zhang A; Zimmerman Z; Zugmaier G; Topp MS
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1498-1504. PubMed ID: 31002989
[TBL] [Abstract][Full Text] [Related]
17. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.
Locatelli F; Maschan A; Boissel N; Strocchio L; Alam N; Pezzani I; Brescianini A; Kreuzbauer G; Baruchel A
Pediatr Blood Cancer; 2022 Apr; 69(4):e29562. PubMed ID: 35044079
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Study of Blinatumomab in the Treatment of Adult Relapsed/Refractory Ph-Negative Acute B-Lymphoblastic Leukemia].
Ouyang M; Zhang YY; Shi L; Liu JX; Wang CJ; Wang F; Zhang Y; Li Y; Zhang MX; Hu WQ; Ren HY; Jiang B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1352-1357. PubMed ID: 37846684
[TBL] [Abstract][Full Text] [Related]
19. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
20. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.
Aldoss I; Song J; Stiller T; Nguyen T; Palmer J; O'Donnell M; Stein AS; Marcucci G; Forman S; Pullarkat V
Am J Hematol; 2017 Sep; 92(9):858-865. PubMed ID: 28494518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]